成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. JAK/STAT Signaling Protein Tyrosine Kinase/RTK Autophagy Apoptosis Metabolic Enzyme/Protease
  2. EGFR Autophagy Apoptosis Endogenous Metabolite
  3. Genistein

Genistein  (Synonyms: 染料木素; NPI 031L)

目錄號(hào): HY-14596 純度: 99.82%
COA 產(chǎn)品使用指南 技術(shù)支持

Genistein是一種大豆異黃酮,是一種多重的酪氨酸激酶 (tyrosine kinases,比如 EGFR) 抑制劑,是對(duì)多種癌癥的化療劑,主要通過改變細(xì)胞凋亡 (apoptosis),細(xì)胞周期和血管生成以及抑制轉(zhuǎn)移。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Genistein Chemical Structure

Genistein Chemical Structure

CAS No. : 446-72-0

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)(單位)同一產(chǎn)品試用裝僅限申領(lǐng)一次,同一機(jī)構(gòu)(單位)一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ¥550
In-stock
100 mg ¥500
In-stock
500 mg ¥880
In-stock
1 g   詢價(jià)  
5 g   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Genistein:

MCE 顧客使用本產(chǎn)品發(fā)表的 49 篇科研文獻(xiàn)

  • 生物活性

  • 實(shí)驗(yàn)參考方法

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.

IC50 & Target[1]

EGFR

0.6 μM (IC50, Cell Assay)

細(xì)胞效力
(Cellular Effect)
Cell Line Type Value Description References
A-431 EC50
108 μM
Compound: 2
Antiproliferative activity against human A431 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay
Antiproliferative activity against human A431 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay
[PMID: 24456004]
A-431 EC50
278 μM
Compound: 2
Antiproliferative activity against human A431 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay
Antiproliferative activity against human A431 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay
[PMID: 24456004]
A549 IC50
43.09 μM
Compound: 1
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
[PMID: 21129977]
A549 IC50
64 μM
Compound: Gen
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
AGS IC50
41.67 μM
Compound: 1
Cytotoxicity against human AGS cells after 72 hrs by MTT assay
Cytotoxicity against human AGS cells after 72 hrs by MTT assay
[PMID: 21129977]
B16-F10 IC50
79.21 μM
Compound: 3
Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
[PMID: 27720556]
BALB/3T3 IC50
183.9 μM
Compound: 9
Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay
Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay
[PMID: 10096863]
Balb/MK IC50
9.1 μM
Compound: Genistein
Tested for antiproliferative activity using mouse epidermal keratinocytes cell line (BALB/MK)
Tested for antiproliferative activity using mouse epidermal keratinocytes cell line (BALB/MK)
[PMID: 7608909]
BJ EC50
> 86.2069 μM
Compound: 2
Antiproliferative activity against human BJ cells after 72 hrs by CelTiter-Glo assay
Antiproliferative activity against human BJ cells after 72 hrs by CelTiter-Glo assay
[PMID: 29407975]
BT-20 IC50
46 μM
Compound: Genistein
Antiproliferative activity against human BT20 cell line by MTT assay
Antiproliferative activity against human BT20 cell line by MTT assay
[PMID: 16789737]
BXPC-3 IC50
30 μM
Compound: Genistein
Antiproliferative activity against human BxPC3 cell line by MTT assay
Antiproliferative activity against human BxPC3 cell line by MTT assay
[PMID: 16789737]
BXPC-3 IC50
79 μM
Compound: Gen
Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
C8166 EC50
13.9 μg/mL
Compound: 7
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis
[PMID: 24794743]
C8166 CC50
36.2 μg/mL
Compound: 7
Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
[PMID: 24794743]
Caco-2 IC50
> 100 μM
Compound: 1
Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay
Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay
[PMID: 21129977]
COLO 201 IC50
73 μM
Compound: Gen
Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
COLO357 IC50
50 μM
Compound: Genistein
Antiproliferative activity against human COLO357 cell line by MTT assay
Antiproliferative activity against human COLO357 cell line by MTT assay
[PMID: 16789737]
DLD-1 IC50
50 μM
Compound: 51
Antiproliferative activity against human DLD-1 cells assessed as reduction in cell viability by MTS assay
Antiproliferative activity against human DLD-1 cells assessed as reduction in cell viability by MTS assay
[PMID: 33445154]
DU-145 IC50
> 100 μM
Compound: Genistein
Cytotoxicity against human androgen-independent DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay
Cytotoxicity against human androgen-independent DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay
[PMID: 26341135]
DU-145 ED50
2.39 μg/mL
Compound: 5
Cytotoxicity against human DU145 cells after 6 days by MTT assay
Cytotoxicity against human DU145 cells after 6 days by MTT assay
[PMID: 12088420]
DU-145 IC50
47.29 μM
Compound: 1
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
[PMID: 21129977]
HCT-116 IC50
34.9 μM
Compound: 1
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
[PMID: 21129977]
HEK293 IC50
> 100 μM
Compound: Genistein
Inhibition of Src (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay
Inhibition of Src (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay
[PMID: 25205190]
HEK293 IC50
22 μM
Compound: genistein
Antagonist activity at human recombinant LXRbeta expressed in HEK293 cells by luciferase reporter gene assay
Antagonist activity at human recombinant LXRbeta expressed in HEK293 cells by luciferase reporter gene assay
[PMID: 18343126]
HEK293 IC50
25.12 μM
Compound: Genistein
Inhibition of EGFR (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay
Inhibition of EGFR (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay
[PMID: 25205190]
HEK293 IC50
31 μM
Compound: genistein
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay
Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay
[PMID: 18343126]
HEK293 IC50
58.18 μM
Compound: Genistein
Inhibition of Fyn (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay
Inhibition of Fyn (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay
[PMID: 25205190]
HEK293 IC50
67.99 μM
Compound: Genistein
Inhibition of Bmx (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay
Inhibition of Bmx (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay
[PMID: 25205190]
HepG2 IC50
> 100 μM
Compound: Genistein
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
[PMID: 26896708]
HepG2 EC50
67.6945 μM
Compound: 2
Antiproliferative activity against human HepG2 cells after 72 hrs by CelTiter-Glo assay
Antiproliferative activity against human HepG2 cells after 72 hrs by CelTiter-Glo assay
[PMID: 29407975]
Hs-578T ED50
3.5 μg/mL
Compound: 5
Cytotoxicity against human Hs 578T cells after 6 days by MTT assay
Cytotoxicity against human Hs 578T cells after 6 days by MTT assay
[PMID: 12088420]
Hs746T ED50
5.82 μg/mL
Compound: 5
Cytotoxicity against human Hs 746T cells after 6 days by MTT assay
Cytotoxicity against human Hs 746T cells after 6 days by MTT assay
[PMID: 12088420]
HT-29 IC50
50 μM
Compound: Gen
Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
HT-29 IC50
52.78 μM
Compound: 1
Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay
[PMID: 21129977]
Huh-7 CC50
> 50 μM
Compound: 23
Cytotoxicity against human Huh7.5.1 cells by MTT assay
Cytotoxicity against human Huh7.5.1 cells by MTT assay
[PMID: 22445328]
Huh-7 EC50
14.4 μM
Compound: 23
Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay
Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay
[PMID: 22445328]
Huh-7 IC50
20 μM
Compound: Genistein
Antiplasmodial activity against liver sporozoite stage of Plasmodium berghei ANKA expressing GFP infected in human HuH7 cells assessed as inhibition of parasite development after 24 hrs by qRT-PCR analysis
Antiplasmodial activity against liver sporozoite stage of Plasmodium berghei ANKA expressing GFP infected in human HuH7 cells assessed as inhibition of parasite development after 24 hrs by qRT-PCR analysis
[PMID: 24125849]
HUVEC IC50
88 μM
Compound: 13
Cytotoxicity against HUVEC after 24 hrs by MTT assay
Cytotoxicity against HUVEC after 24 hrs by MTT assay
[PMID: 17591441]
Ishikawa IC50
0.51 μM
Compound: genistein
Estrogenic activity in human Ishikawa cells assessed as induction of alkaline phosphatase activity after 4 days by para-nitrophenol release assay
Estrogenic activity in human Ishikawa cells assessed as induction of alkaline phosphatase activity after 4 days by para-nitrophenol release assay
[PMID: 12502307]
K562 IC50
17.56 μM
Compound: 1
Growth inhibition of K562 cells by XTT assay after 5 days
Growth inhibition of K562 cells by XTT assay after 5 days
[PMID: 17411092]
KOPN-8 EC50
> 86.2069 μM
Compound: 2
Antiproliferative activity against human KOPN8 cells after 72 hrs by CelTiter-Glo assay
Antiproliferative activity against human KOPN8 cells after 72 hrs by CelTiter-Glo assay
[PMID: 29407975]
L02 IC50
> 100 μM
Compound: Genistein
Cytotoxicity against human LO2 cells after 48 hrs by MTT assay
Cytotoxicity against human LO2 cells after 48 hrs by MTT assay
[PMID: 26896708]
LN-229 IC50
44 μM
Compound: Gen
Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
LNCaP IC50
24 μM
Compound: Genistein
Antiproliferative activity against human LNCAP cells after 72 hrs by MTS assay
Antiproliferative activity against human LNCAP cells after 72 hrs by MTS assay
[PMID: 29456113]
LNCaP IC50
30.65 μM
Compound: 1
Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay
Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay
[PMID: 21129977]
LNCaP IC50
31.7 μM
Compound: Genistein
Antiproliferative activity against human LNCAP cells after 72 hrs in presence of enzalutamide by MTS assay
Antiproliferative activity against human LNCAP cells after 72 hrs in presence of enzalutamide by MTS assay
[PMID: 29456113]
LNCaP IC50
37.4 μM
Compound: Genistein
Cytotoxicity against human androgen-dependent LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay
Cytotoxicity against human androgen-dependent LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay
[PMID: 26341135]
LNCaP IC50
65 μM
Compound: Genistein
Inhibition of chymotrypsin-like activity of human 26S proteasome extracted from human LNCap cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 60 mins by fluorescence based method
Inhibition of chymotrypsin-like activity of human 26S proteasome extracted from human LNCap cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 60 mins by fluorescence based method
[PMID: 30776692]
LNCaP-Clone-FGC ED50
25.45 μg/mL
Compound: 5
Cytotoxicity against human LNCaP-FGC cells after 6 days by MTT assay
Cytotoxicity against human LNCaP-FGC cells after 6 days by MTT assay
[PMID: 12088420]
LoVo IC50
15.88 μM
Compound: 1
Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
[PMID: 21129977]
MCF7 IC50
> 30 μM
Compound: genistein
Cytotoxicity against human MCF7 cells after 72 hrs
Cytotoxicity against human MCF7 cells after 72 hrs
[PMID: 10075742]
MCF7 IC50
1 μM
Compound: genistein
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 20813524]
MCF7 IC50
26 μM
Compound: genistein
Inhibition of phorbol ester-induced ornithine decarboxylase in human MCF7 cells after 6 hrs
Inhibition of phorbol ester-induced ornithine decarboxylase in human MCF7 cells after 6 hrs
[PMID: 10075742]
MCF7 IC50
50 nM
Compound: Genistein
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
[PMID: 33257172]
MCF7 IC50
62.71 μM
Compound: 1
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
[PMID: 21129977]
MCF7 IC50
8.8 μM
Compound: 28
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
[PMID: 21354800]
MDA-MB-231 IC50
43 μM
Compound: Gen
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
MDCK IC50
6.9 μM
Compound: 28
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
[PMID: 21354800]
Melan-a IC50
57.83 μM
Compound: 6
Inhibition of melanin formation in mouse Melan-a cells after 5 days by ELISA
Inhibition of melanin formation in mouse Melan-a cells after 5 days by ELISA
[PMID: 20022495]
NCI-H460 IC50
47 μM
Compound: Gen
Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
Neutrophil IC50
0.54 μg/mL
Compound: Genistein
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins
[PMID: 21353775]
Neutrophil IC50
0.69 μM
Compound: Genistein
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced superoxide anion production treated 5 mins before FMLP addition measured after 10 mins
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced superoxide anion production treated 5 mins before FMLP addition measured after 10 mins
[PMID: 23822585]
Neutrophil IC50
1.11 μM
Compound: Genistein
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLF/cytochalasin B-induced superoxide anion generation preincubated for 5 mins followed by fMLF addition after priming with CB for 3 mins by spectrophotometric analysis
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLF/cytochalasin B-induced superoxide anion generation preincubated for 5 mins followed by fMLF addition after priming with CB for 3 mins by spectrophotometric analysis
[PMID: 32359855]
Neutrophil IC50
6.99 μg/mL
Compound: Genistein
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins
[PMID: 21353775]
PANC-1 IC50
87 μM
Compound: Gen
Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
PC-3 IC50
50 μM
Compound: Genistein
Antiproliferative activity against human PC3 cell line by MTT assay
Antiproliferative activity against human PC3 cell line by MTT assay
[PMID: 16789737]
PC-3 IC50
65.17 μM
Compound: 1
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
[PMID: 21129977]
PC-3 IC50
68.6 μM
Compound: Genistein
Cytotoxicity against human androgen-independent PC3 cells assessed as cell cell viability after 3 days by WST-1 cell proliferation assay
Cytotoxicity against human androgen-independent PC3 cells assessed as cell cell viability after 3 days by WST-1 cell proliferation assay
[PMID: 26341135]
RAW IC50
18.1 μM
Compound: genistein
Inhibition of 1 ug/ml LPS-stimulated TNFalpha accumulation in RAW 264 cells after 24 hrs
Inhibition of 1 ug/ml LPS-stimulated TNFalpha accumulation in RAW 264 cells after 24 hrs
[PMID: 17320246]
RAW264.7 IC50
> 1 μM
Compound: 19
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pretreated for 1 hr followed by LPS-stimulation and measured after 24 hrs by Griess assay
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pretreated for 1 hr followed by LPS-stimulation and measured after 24 hrs by Griess assay
[PMID: 29932657]
RAW264.7 IC50
> 50 μM
Compound: 10
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay
[PMID: 25592708]
RAW264.7 IC50
11.4 μM
Compound: Genistein
Antiosteoporotic activity in mouse RAW264.7 cells assessed as inhibition of RANKL-induced osteoclast differentiation after 4 to 5 days by TRAP assay
Antiosteoporotic activity in mouse RAW264.7 cells assessed as inhibition of RANKL-induced osteoclast differentiation after 4 to 5 days by TRAP assay
[PMID: 28169537]
RAW264.7 IC50
19.1 μM
Compound: Genistein
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production treated 2 hrs before LPS challenge measured after 24 hrs by ELISA
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production treated 2 hrs before LPS challenge measured after 24 hrs by ELISA
[PMID: 21288727]
RAW264.7 IC50
26 μM
Compound: Genistein
Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 24 hrs by Griess reagent
Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 24 hrs by Griess reagent
[PMID: 20363145]
RAW264.7 IC50
26.5 μM
Compound: Genistein
Inhibition of LPS-induced TNFalpha release in mouse RAW264.7 cells pretreated 1 hr before LPS challenge by enzyme immunoassay
Inhibition of LPS-induced TNFalpha release in mouse RAW264.7 cells pretreated 1 hr before LPS challenge by enzyme immunoassay
[PMID: 19278854]
SEM EC50
59.338 μM
Compound: 2
Antiproliferative activity against human SEM cells after 72 hrs by CelTiter-Glo assay
Antiproliferative activity against human SEM cells after 72 hrs by CelTiter-Glo assay
[PMID: 29407975]
Sf9 IC50
> 100 μM
Compound: 10
Inhibition of His6-tagged human recombinant DNMT3A/DNMT3L expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid
Inhibition of His6-tagged human recombinant DNMT3A/DNMT3L expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid
[PMID: 25406944]
Sf9 IC50
30 μM
Compound: 10
Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintil
Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintil
[PMID: 25406944]
SK-BR-3 EC50
403 μM
Compound: 2
Antiproliferative activity against human SKBR3 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay
Antiproliferative activity against human SKBR3 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay
[PMID: 24456004]
SK-BR-3 IC50
96.7 μM
Compound: 1
Cytotoxicity against human SKBR3 cells after 72 hrs by SRB assay
Cytotoxicity against human SKBR3 cells after 72 hrs by SRB assay
[PMID: 21129977]
SK-BR-3 EC50
97 μM
Compound: 2
Antiproliferative activity against human SKBR3 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay
Antiproliferative activity against human SKBR3 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay
[PMID: 24456004]
SK-MEL-2 IC50
36 μM
Compound: Gen
Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
SUP-B15 EC50
> 86.2069 μM
Compound: 2
Antiproliferative activity against human SUP-B15 cells after 72 hrs by CelTiter-Glo assay
Antiproliferative activity against human SUP-B15 cells after 72 hrs by CelTiter-Glo assay
[PMID: 29407975]
T47D IC50
48 μM
Compound: Gen
Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
T98G IC50
89.41 μM
Compound: 1
Cytotoxicity against human T98G cells after 72 hrs by SRB assay
Cytotoxicity against human T98G cells after 72 hrs by SRB assay
[PMID: 21129977]
U-87MG ATCC IC50
55 μM
Compound: Gen
Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay
[PMID: 28654265]
U-937 IC50
> 100 μM
Compound: 5
Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay
[PMID: 17158054]
U-937 IC50
48 μM
Compound: 5
Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay
[PMID: 17158054]
U-937 IC50
72 μM
Compound: 5
Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay
[PMID: 17158054]
UoC-B1 EC50
35.6958 μM
Compound: 2
Antiproliferative activity against human UOCB1 cells after 72 hrs by CelTiter-Glo assay
Antiproliferative activity against human UOCB1 cells after 72 hrs by CelTiter-Glo assay
[PMID: 29407975]
Ventricular myocyte IC50
11 μM
Compound: Genistein
Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes
Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes
[PMID: 22761000]
Ventricular myocyte IC50
20 μM
Compound: Genistein
Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes
Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes
[PMID: 22761000]
體外研究
(In Vitro)

Genistein 抑制血清刺激的 MCF-7 和 T47D ER+ 細(xì)胞生長(zhǎng),染料排斥的 IC50 值分別為 7.6 和 8.7 μg/mL,以及 8.7 和 10.6 μg/mL 分別由[3H]胸腺嘧啶摻入。這些值類似于通過 MTT 測(cè)定獲得的 MCF-7 和 T47D ER+ 細(xì)胞的 IC50 值,分別為 9.4 和 7 μg/mL。此外,在 8 小時(shí)的孵育期內(nèi),與對(duì)照細(xì)胞相比,濃度高達(dá) 20 μg/mL 的 Genistein 不會(huì)改變 MTT 線粒體減少。此外,在 IC50 濃度下,Biochanin A 或大豆苷元均未發(fā)現(xiàn)干擾 MTT 測(cè)定。因此,MTT 法可有效確定所研究系統(tǒng)中 Genistein 在濃度低于 20 μg/mL 時(shí)的生長(zhǎng)抑制作用[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

Bisphenol A (BPA) 單獨(dú)處理和聯(lián)合 Genistein 對(duì) STD 或 HFD 喂養(yǎng)大鼠肝臟中 LC3II 和 PPARα 的蛋白表達(dá)無顯著影響 (P>0.05;P>0.05)。與 HFD 組或 HFD-BPA 組相比,觀察到在大鼠中添加 Genistein 后肝臟中 PPARγ 的蛋白表達(dá)顯著降低[2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
分子量

270.24

Formula

C15H10O5

CAS 號(hào)
性狀

固體

顏色

White to yellow

中文名稱

染料木素;染料木黃酮;金雀異黃酮

結(jié)構(gòu)分類
初始來源
運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 1 year
-20°C 6 months
溶解性數(shù)據(jù)
細(xì)胞實(shí)驗(yàn): 

DMSO 中的溶解度 : ≥ 100 mg/mL (370.04 mM; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響,請(qǐng)使用新開封的 DMSO)

H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

配制儲(chǔ)備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 3.7004 mL 18.5021 mL 37.0041 mL
5 mM 0.7401 mL 3.7004 mL 7.4008 mL
查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?年內(nèi)使用, -20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用。

  • 摩爾計(jì)算器

  • 稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動(dòng)物實(shí)驗(yàn):

請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液,再依次添加助溶劑:
——為保證實(shí)驗(yàn)結(jié)果的可靠性,澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的工作液,建議您現(xiàn)用現(xiàn)配,當(dāng)天使用;
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的方式助溶

  • 方案 一

    請(qǐng)依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 3.75 mg/mL (13.88 mM); 澄清溶液

    此方案可獲得 ≥ 3.75 mg/mL(飽和度未知)的澄清溶液。

    1 mL 工作液為例,取 100 μL 37.5 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中,混合均勻;再向上述體系中加入 50 μL Tween-80,混合均勻;然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL

    生理鹽水的配制:將 0.9 g 氯化鈉,溶解于 ddH?O 并定容至 100 mL,可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請(qǐng)依序添加每種溶劑: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 3 mg/mL (11.10 mM); 澄清溶液

    此方案可獲得 ≥ 3 mg/mL(飽和度未知)的澄清溶液。

    1 mL 工作液為例,取 100 μL 30.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中,混合均勻。

    2 g SBE-β-CD(磺丁基醚 β-環(huán)糊精)粉末定容于 10 mL 的生理鹽水中,完全溶解至澄清透明。

以下溶解方案,請(qǐng)直接配制工作液。建議現(xiàn)用現(xiàn)配,在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比; 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的方式助溶。

  • 方案 一

    請(qǐng)依序添加每種溶劑: 50% PEG300    50% Saline

    Solubility: 5 mg/mL (18.50 mM); 懸濁液; 超聲助溶

動(dòng)物溶解方案計(jì)算器
請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息:

給藥劑量

mg/kg

動(dòng)物的平均體重

g

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

由于實(shí)驗(yàn)過程有損耗,建議您多配一只動(dòng)物的量
請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠,建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
方案所需 助溶劑 包括:DMSO, ,均可在 MCE 網(wǎng)站選購(gòu)。 ,Tween 80,均可在 MCE 網(wǎng)站選購(gòu)。
計(jì)算結(jié)果
工作液所需濃度 : mg/mL
儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO(母液濃度為 mg/mL)。
您所需的儲(chǔ)備液濃度超過該產(chǎn)品的實(shí)測(cè)溶解度,以下方案僅供參考,如有需要,請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液,加入 μL 。 μL ,混合均勻至澄清,再加 μL Tween 80,混合均勻至澄清,再加 μL 生理鹽水。
連續(xù)給藥周期超過半月以上,請(qǐng)謹(jǐn)慎選擇該方案。
請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài),從左到右依次添加助溶劑。您可采用超聲加熱 (超聲清洗儀,建議頻次 20-40 kHz),渦旋吹打等方式輔助溶解。
純度 & 產(chǎn)品資料

純度: 99.82%

參考文獻(xiàn)
Cell Assay
[1]

The IC50 values for Genistein are determined by the MTT assay. Briefly, the MTT assay is a colorimetric assay that is based on the ability of living but not dead cells to reduce a tetrazolium-based compound to a blue formazan product. The formazan crystals are solubilized in DMSO, and the absorbance is measured at 540 nm. The absorbance at 540 nm is proportional to the number of viable cells. The lC50 values obtained with the MTT assay are compared with the lC50 values obtained by counting viable cells using trypan blue dye exclusion and by tritiated thymidine incorporation into DNA[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2][3]

Mice[2]
Balb/c male mice are used. Genistein is administered as follows: On days 1-30, Genistein once daily, interaperitoneally injecting. Morphine plus Genistein is administered as follows: On days 1-30, Genistein once daily plus morphine, interaperitoneally injecting (17, 18). The same volume of saline is administered. Mice are randomly divided into 8 groups (n=6). 1) Normal saline group (1 mL DW/daily); 2) Morphine treated group; 3) Genistein 1 mg/kg treated group; 4) Genistein 2 mg/kg treated group 5) Genistein 4 mg/kg treated group; 6) Morphine plus Genistein 1 mg/kg treated group; 7) Morphine plus Genistein 2 mg/kg treated group; 8) Morphine plus Genistein 4 mg/kg treated group.
Rats[3]
Male 8-week-old Wistar rats (150-180g) are used. After one week acclimation, all rats are randomly divided into 8 groups with 10 rats per group and treated for 35 weeks as follows: (1) STD group is fed with rodent standard chow diet (STD); (2) STD-BPA group is fed with STD and administered with BPA (50 μg/kg/day); (3) STD-(BPA+G) group is fed with STD and administered with BPA (50 μg/kg/day) plus Genistein (10 mg/kg/day); (4) STD-G group is fed with STD and administered with Genistein (10 mg/kg/day); (5) HFD group received high-fat diet (HFD); (6) HFD-BPA group is fed with HFD and administered with BPA (50 μg/kg/day); (7) STD-(BPA+G) group is fed with HFD and administered with BPA (50 μg/kg/day) plus Genistein (10 mg/kg/day); (8) HFD-G group is fed with HFD and administrated with Genistein (10 mg/kg/day). All the male genitors are treated for 35 weeks consecutively. The details of BPA (50 μg/kg/day) and Genistein (10 mg/kg/day) treatment methods have been described previously: BPA is dissolved in corn oil and diluted with three stock solutions (20, 40, 80, and 120 μg/mL).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

參考文獻(xiàn)

完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?年內(nèi)使用, -20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.7004 mL 18.5021 mL 37.0041 mL 92.5104 mL
5 mM 0.7401 mL 3.7004 mL 7.4008 mL 18.5021 mL
10 mM 0.3700 mL 1.8502 mL 3.7004 mL 9.2510 mL
15 mM 0.2467 mL 1.2335 mL 2.4669 mL 6.1674 mL
20 mM 0.1850 mL 0.9251 mL 1.8502 mL 4.6255 mL
25 mM 0.1480 mL 0.7401 mL 1.4802 mL 3.7004 mL
30 mM 0.1233 mL 0.6167 mL 1.2335 mL 3.0837 mL
40 mM 0.0925 mL 0.4626 mL 0.9251 mL 2.3128 mL
50 mM 0.0740 mL 0.3700 mL 0.7401 mL 1.8502 mL
60 mM 0.0617 mL 0.3084 mL 0.6167 mL 1.5418 mL
80 mM 0.0463 mL 0.2313 mL 0.4626 mL 1.1564 mL
100 mM 0.0370 mL 0.1850 mL 0.3700 mL 0.9251 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱:

 

* 需求量:

* 客戶姓名:

 

* Email:

* 電話:

 

* 公司或機(jī)構(gòu)名稱:

   留言給我們:

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱:
Genistein
目錄號(hào):
HY-14596
需求量: